NO20081079L - Nytt salt III - Google Patents

Nytt salt III

Info

Publication number
NO20081079L
NO20081079L NO20081079A NO20081079A NO20081079L NO 20081079 L NO20081079 L NO 20081079L NO 20081079 A NO20081079 A NO 20081079A NO 20081079 A NO20081079 A NO 20081079A NO 20081079 L NO20081079 L NO 20081079L
Authority
NO
Norway
Prior art keywords
fresh salt
salt iii
solvate
salt
iii
Prior art date
Application number
NO20081079A
Other languages
English (en)
Inventor
Julien Giovannini
Bo-Goran Josefsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081079(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20081079L publication Critical patent/NO20081079L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

N-{2-[((25)-3-{[l-(4-klorbenzyl)piperidin-4-yl]amino}-2-hydroksy-2-metylpropyl)-oksy]-4-hydroksyfenyl}acetamid hemi-fumarat eller et solvat derav, farmasøytiske preparater som inneholder saltet eller solvatet og anvendelse av saltet eller solvatet i terapi.
NO20081079A 2005-08-02 2008-02-29 Nytt salt III NO20081079L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0501769 2005-08-02
PCT/SE2006/000922 WO2007015668A1 (en) 2005-08-02 2006-07-31 New salt iii

Publications (1)

Publication Number Publication Date
NO20081079L true NO20081079L (no) 2008-02-29

Family

ID=37708913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081079A NO20081079L (no) 2005-08-02 2008-02-29 Nytt salt III

Country Status (16)

Country Link
US (1) US20080176902A1 (no)
EP (1) EP1912944A1 (no)
JP (1) JP2009503066A (no)
KR (1) KR20080031370A (no)
CN (1) CN101238104A (no)
AR (1) AR056013A1 (no)
AU (1) AU2006276346A1 (no)
BR (1) BRPI0614535A2 (no)
CA (1) CA2617406A1 (no)
IL (1) IL188484A0 (no)
MX (1) MX2008001114A (no)
NO (1) NO20081079L (no)
TW (1) TW200734305A (no)
UY (1) UY29713A1 (no)
WO (1) WO2007015668A1 (no)
ZA (1) ZA200800488B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031033A1 (en) * 1998-11-20 2000-06-02 F. Hoffmann-La Roche Ag Piperidine ccr-3 receptor antagonists
CO5300399A1 (es) * 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
AR028948A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0021670D0 (en) * 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
JP2009503066A (ja) 2009-01-29
AR056013A1 (es) 2007-09-12
BRPI0614535A2 (pt) 2011-04-05
WO2007015668A1 (en) 2007-02-08
ZA200800488B (en) 2008-12-31
US20080176902A1 (en) 2008-07-24
TW200734305A (en) 2007-09-16
MX2008001114A (es) 2008-03-11
EP1912944A1 (en) 2008-04-23
KR20080031370A (ko) 2008-04-08
UY29713A1 (es) 2007-02-28
CA2617406A1 (en) 2007-02-08
AU2006276346A1 (en) 2007-02-08
IL188484A0 (en) 2008-04-13
CN101238104A (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
RS52283B (sr) 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n- metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2- indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji
FIC20200014I1 (fi) Fostamatinibi tai fostamatinibin farmaseuttisesti hyväksyttävä suola tai fostamatinibin hydraatti, solvaatti, tai N-oksidi, tai fostamatinibin farmaseuttisesti hyväksyttävä suola, erityisesti fostamatinibi dinatrium, valinnaisesti hydraatin muodossa
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DE602005016601D1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
SG157378A1 (en) Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
NO20033566L (no) Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler
NO20033565L (no) Acylerte indanylaminer og deres anvendelse som farmasöytiske midler
NO20081081L (no) Nytt salt II
DE602004031462D1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
FR2876590B1 (fr) Appareil d'anesthesie
TW200609204A (en) Sulfonamide derivatives, preparation thereof and therapeutic application thereof
ECSP10010265A (es) Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil)
UA100364C2 (xx) Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
NO20055367L (no) Kombinasjoner som innbefatter paroksetin og 2-(S)-4-fluor-2-metyl-fenyl)-piperazin-1-karboksylsyer (1-(R)-(3,5-bis-trifluor-2-metyl-fenyl)-etyl]metylamid for behandling av depresjon og/eller angst
IS2473B (is) Samsetning sem inniheldur N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-(1,3,4-oxadíasól-2-ýl)fenýl)pýridín-3-súlfónamíð (ZD4054), eða lyfjafræðilega viðurkennt salt þess, og EGFR TKI, eða lyfjafræðilega viðurkennt salt þess
NO20081079L (no) Nytt salt III
NO20080133L (no) Azolopyridin-2-on derivater som lipase og fosfolipaseinhibitorer
ATE501719T1 (de) Methoden und zusammensetzungen zur beruhigung von mund- und nasenschleimhäuten
IL177169A0 (en) Use of n- (2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
NO20081080L (no) Nytt salt I
SE0402284D0 (sv) New heterocyclic amides
DK1594868T3 (da) 8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer
EA200501818A1 (ru) Индазолы, обладающие анальгетической активностью
MY142260A (en) New association of agomelatine and a noradrenaline reuptake inhibitor, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application